Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and PNET
This study is currently recruiting participants.
Verified February 2012 by Children's Hospital Colorado
Sponsor:
Children's Hospital Colorado
Information provided by (Responsible Party):
Jennifer Madden, Children's Hospital Colorad
ClinicalTrials.gov Identifier:
NCT01542736
First received: February 27, 2012
Last updated: March 1, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.
Condition | Intervention | Phase |
---|---|---|
Metastatic Medulloblastoma High Risk Supratentorial PNET Metastatic PNET |
Drug: Carboplatin Drug: Vincristine Radiation: 24 Gy |
Phase 2 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET |
Resource links provided by NLM:
Further study details as provided by Children's Hospital Colorado:
Primary Outcome Measures:
- Event-free Survival [ Time Frame: up to 5 years ] [ Designated as safety issue: Yes ]MRIs of the head and spine
- Overall Survival [ Time Frame: up to 5 years ] [ Designated as safety issue: Yes ]
- Intellectual Competence measured by number of cognitive deficits [ Time Frame: up to 5 years ] [ Designated as safety issue: Yes ]Neurophsychological testing will be performed 3-6 months after radiation in completed.
Estimated Enrollment: | 10 |
Study Start Date: | May 2007 |
Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Treatment
Reduced dose craniospinal radiation with concurrent carboplatin and vincristine administration
|
Drug: Carboplatin Drug: Vincristine Radiation: 24 Gy |
Eligibility
Ages Eligible for Study: | 3 Years to 25 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age greater than 3 years and less than 25 years
- Patients with classic histology or desmoplastic histology metastatic medulloblastoma by histological diagnosis and by head and spine MRI.
- Patients with anaplastic histology will be excluded.
- Patients with high-risk supratentorial, non-metastatic, PNET
- Patients with metastatic PNET
- Newly diagnosed patients who have not received prior therapy, with the exception of one short course of emergent chemotherapy in newly presenting patients with neurological compromise per provider decision
- Only patients who are expected to survive at least 6 weeks will be eligible for this study.
Exclusion Criteria:
- Patients who are pregnant may not be treated on this study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01542736
Locations
United States, Colorado | |
Children's Hospital Colorado | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Jennifer Madden, CPNP 720-777-6772 Jennifer.Madden@childrenscolorado.org | |
Principal Investigator: Jennifer Madden, RN, CPNP |
Sponsors and Collaborators
Children's Hospital Colorado
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
No publications provided
Responsible Party: | Jennifer Madden, Pediatric Nurse Practitioner, NeuroOncology, Assistant Professor, Children's Hospital Colorad |
ClinicalTrials.gov Identifier: | NCT01542736 History of Changes |
Other Study ID Numbers: | COMIRB 06-1151 |
Study First Received: | February 27, 2012 |
Last Updated: | March 1, 2012 |
Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
Medulloblastoma Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Neuroectodermal Tumors, Primitive, Peripheral Glioma Neoplasms, Neuroepithelial Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |
Vincristine Carboplatin Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents, Phytogenic Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on October 17, 2012